Patient characteristics
toxicity, Ewing sarcoma
EWING SARCOMA
A total of 10 patients enrolled between December 2019 and August 2021. All 10 patients received at least one dose of study drug and were included in the primary efficacy and toxicity analyses. The study was closed in December 2021 prior to completion of accrual due to unanticipated inability to extend the expiration of the final ganitumab stock without planned further production. No unplanned analyses were conducted prior to this unanticipated early closure due to lack of available drug.Of the 10 patients, 7 were male and the median age at enrollment was 25.7 years (range 12.3–40.1; Table Characteristics of study participants with relapsed Ewing sarcoma (